MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
0.7110
-0.0107
-1.48%
Opening 12:55 04/22 EDT
OPEN
0.7220
PREV CLOSE
0.7217
HIGH
0.7700
LOW
0.7077
VOLUME
97.67K
TURNOVER
0
52 WEEK HIGH
122.02
52 WEEK LOW
0.5750
MARKET CAP
6.18M
P/E (TTM)
-0.0796
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLXN last week (0414-0418)?
Weekly Report · 1d ago
Weekly Report: what happened at SLXN last week (0407-0411)?
Weekly Report · 04/14 09:46
Weekly Report: what happened at SLXN last week (0331-0404)?
Weekly Report · 04/07 09:45
Silexion Therapeutics Corp. (Exact name of registrant as specified in its charter) Annual Report (Form 10-K) for the fiscal year ended December 31, 2024
Press release · 04/07 03:50
Weekly Report: what happened at SLXN last week (0324-0328)?
Weekly Report · 03/31 09:49
Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion
TipRanks · 03/29 15:25
Silexion Therapeutics Expands SIL204 Development Plan
TipRanks · 03/28 12:56
Silexion Therapeutics announces expanded development plan for SIL204
TipRanks · 03/28 12:41
More
About SLXN
More
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Recently
Symbol
Price
%Change

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.